Understanding Your Rights as an Investor
As an investor in PepGen Inc. (NASDAQ: PEPG), you may be wondering about your options for recovering potential financial losses due to recent events involving the company. It's essential to stay informed about any legal developments regarding the class actions that may affect your investment. If you purchased shares during the class period, which spans from March 7, 2024, to March 3, 2025, you are encouraged to consider your legal rights.
PepGen's Clinical Journey and Allegations
PepGen is a clinical-stage biotechnology company dedicated to developing oligonucleotide therapeutics aimed at treating serious neuromuscular and neurological diseases. Its leading product candidate, PGN-EDO51, targets Duchenne muscular dystrophy (DMD). Throughout its clinical trials, particularly the CONNECT2 study, several claims have surfaced regarding the safety and efficacy of this treatment.
Class Action Lawsuit Against PepGen
The Portnoy Law Firm has alerted investors about a class action lawsuit against PepGen, specifically regarding the company's communications surrounding its clinical trials and product safety. The lawsuit alleges that PepGen misled investors about the safety and regulatory approval prospects of PGN-EDO51 and failed to disclose material information about its trials.
Timeline of Key Events in PepGen's Trials
Throughout the class period, significant announcements had a profound impact on the company's stock price. For instance:
- On July 30, 2024, PepGen reported "positive clinical data" from the CONNECT1 study, but analysts criticized the results for not meeting expectations, resulting in a nearly 33% drop in stock.
- On December 16, 2024, PepGen received a clinical hold notice from the FDA that further stressed investor concerns, leading to additional drops in share value.
- The announcement of a temporary dosing pause in January 2025 triggered another decline, as the market reacted to uncertainties regarding safety data and regulatory plans.
- Finally, on March 4, 2025, the voluntary pause of the CONNECT2 study raised further questions, contributing to a significant stock dip.
How to Get Involved
If you are a PepGen investor and are concerned about your financial outcomes, you need to act swiftly. The deadline to file a lead plaintiff motion is approaching, and it’s important to be informed about your options. The Portnoy Law Firm offers consultations at no cost, where you can learn more about your rights in these circumstances.
Contact Information
To discuss your legal rights and options for joining the case, reach out to attorney Lesley F. Portnoy at 310-692-8883 or via email at lesley@portnoylaw.com. They can provide insightful case evaluations and support to those affected by the recent developments with PepGen.
Resources for Investors
It's beneficial for investors to stay updated on the ongoing developments at PepGen. Visit the Portnoy Law Firm's website for more information about the ongoing case, or consult with financial advisors who can help you navigate this challenging situation.
Frequently Asked Questions
What is the class action lawsuit against PepGen about?
The lawsuit concerns allegations that PepGen misled investors regarding the safety and effectiveness of its drug candidate, PGN-EDO51, during clinical trials.
How can I participate in the class action lawsuit?
If you purchased PEPG stocks during the specified class action period, you can consult with the Portnoy Law Firm for guidance on how to join the lawsuit.
What should I do if I’ve experienced losses investing in PepGen?
Contact an attorney from the Portnoy Law Firm to discuss your legal options and potentially recover your investment losses.
What is the deadline for filing a lead plaintiff motion?
The deadline to file a lead plaintiff motion for the class action lawsuit is August 8, 2025.
How can a law firm assist in these situations?
A law firm can provide legal representation, guide you through the filing process, and help maximize your potential recovery from the lawsuit.
